Prevention of respiratory distress syndrome: Cost-effectiveness for managing idiopathic preterm labor

Objectives: This retrospective cohort study aimed to compare the cost-effectiveness of using D10-CaGluconate and D5 1/4NS preparations in normalweightneonatal patients with Respiratory Distress Syndrome (RDS) in Kambang General Hospital, Jambi, Indonesia.Methods: The research was conducted from September 2014 to June 2015. The study participants were divided into two groups; D10-CaGluconatewas administered to 40 patients and D5 1/4NS to 43 patients. Effectiveness was assessed based on the changes in the physical examination results,average weight gain (28.48 and 23.49 g/day), blood glucose levels (26.73 and 26.42 mg/dL), respiratory rate (−12.35 breaths/minute and −7.77breaths/minute), pulse frequency (−10.98 and −8.07 ±), and body temperature (0.013°C and 0.012°C) of the patients in the D10-CaGluconate andD5 1/4NS groups, respectively.Results: The average direct medical costs of using D10-CaGluconate and D5 1/4NS were 458,290 IDR and 408,347 IDR, respectively. The average costeffectivenessratio value of total direct medical costs for D10-CaGluconate preparation was 35,207,467 IDR while that for D5 1/4NS was 33,958,602IDR. The direct medical cost of the incremental cost-effectiveness ratio mean value of the D5 1/4NS preparation that compared to the D10-CaGluconatepreparation was 10,017,210 IDR.Conclusions: The parenteral nutrition preparation of D10-CaGluconate is more cost-effective than that of D5 1/4NS.

Download Full-text

PRS50 - COST-EFFECTIVENESS ANALYSIS OF SURFACTANT THERAPY FOR THE TREATMENT OF RESPIRATORY DISTRESS SYNDROME NEWBORN IN THE RUSSIAN FEDERATION

Value in Health ◽

10.1016/j.jval.2018.09.2444 ◽

2018 ◽

Vol 21 ◽

pp. S412

Author(s):

R. Yagudina ◽

A. Kulikov ◽

V. Serpik

Keyword(s):

Cost Effectiveness ◽

Respiratory Distress Syndrome ◽

Respiratory Distress ◽

Russian Federation ◽

Distress Syndrome ◽

Cost Effectiveness Analysis ◽

Surfactant Therapy ◽

Effectiveness Analysis ◽

The Russian Federation

Download Full-text

PMU31 EARLY COST-EFFECTIVENESS ANALYSIS OF CONTINUOUS MONITORING OF LUNG-AERATION WITH ELECTRICAL IMPEDANCE TOMOGRAPHY IN PRETERM NEONATES WITH RESPIRATORY DISTRESS SYNDROME

Value in Health ◽

10.1016/j.jval.2019.09.1650 ◽

2019 ◽

Vol 22 ◽

pp. S713

Author(s):

A. Voermans ◽

J. Mewes ◽

A. van Kaam ◽

R. Bayford ◽

I. Lepage-Nefkens

Keyword(s):

Cost Effectiveness ◽

Respiratory Distress Syndrome ◽

Respiratory Distress ◽

Continuous Monitoring ◽

Electrical Impedance ◽

Distress Syndrome ◽

Preterm Neonates ◽

Impedance Tomography ◽

Effectiveness Analysis ◽

Lung Aeration

Download Full-text

A Comparative Pharmacoeconomic Assessment of Two Surfactants for the Prevention of Respiratory Distress Syndrome

The Journal of Pediatric Pharmacology and Therapeutics ◽

10.5863/1551-6776-11.1.43 ◽

2006 ◽

Vol 11 (1) ◽

pp. 43-54 ◽

Cited By ~ 2

Author(s):

Joette M. Gdovin ◽

Fernando Moya ◽

Tejal Vishalpura ◽

Amy Grogg

Keyword(s):

Mechanical Ventilation ◽

Cost Effectiveness ◽

Respiratory Distress Syndrome ◽

Respiratory Distress ◽

Preterm Infants ◽

Resource Utilization ◽

Distress Syndrome ◽

Healthcare Resource ◽

Pharmacoeconomic Analysis ◽

Healthcare Resource Utilization

OBJECTIVE The use of exogenous surfactants among preterm infants for the prevention and treatment of respiratory distress syndrome (RDS) has led to economic and cost-effectiveness evaluations of these products. Lucinactant (Surfaxin), a novel, peptide-based, synthetic surfactant, has been shown to significantly reduce RDS-related mortality, compared with the most commonly prescribed animal-derived surfactant, beractant (Survanta). Infants who survive expend significant healthcare resources; therefore, the impact of improved survival through 1-year corrected age was evaluated in a prospectively defined pharmacoeconomic analysis. The objectives of this study were to estimate the healthcare resource utilization, economic impact, and cost-effectiveness of lucinactant versus beractant for the prevention of RDS among surviving very low birth weight (VLBW) preterm infants weighing 600 to 1250 grams. METHODS A decision-analytic model was developed to compare the healthcare resource utilization, economic impact, and cost-effectiveness of lucinactant versus beractant. RESULTS Infants who received lucinactant had fewer neonatal intensive care unit (NICU) days and fewer NICU days on mechanical ventilation compared with infants who received beractant. Total healthcare costs for the initial stay in the NICU were lower by $8,803 among infants who received lucinactant compared with infants who received beractant. The incremental cost per life saved was $40,309 for lucinactant compared with beractant. CONCLUSIONS Administration of lucinactant to surviving VLBW preterm infants resulted in fewer NICU days and fewer NICU days on mechanical ventilation compared with beractant. Fewer NICU days translates into lower total costs among infants who received lucinactant. This comprehensive pharmacoeconomic analysis indicates that lucinactant is a cost-effective therapy for the prevention of RDS among preterm infants.

Download Full-text